Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H de Graaf

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|January 1, 1997
Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancerH de Graaf, W V Dolsma, P H Willemse, et al.
The Journal of Biological Chemistry|September 4, 2003
Alternative splicing of the actin binding domain of human cortactin affects cell migrationAgnes G S H van Rossum, Jos H de Graaf, Ellen Schuuring-Scholtes, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 19, 2014
Invasive Propionibacterium acnes infections in a non-selective patient cohort: clinical manifestations, management and outcomeM Tebruegge, C Jones, H de Graaf, et al.
Anticancer Research|November 1, 1995
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized diseaseH de Graaf, N H Mulder, P H Willemse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodesH de Graaf, P H Willemse, E G de Vries, et al.
The Journal of Infection|November 17, 2021
Immunocompromised children and young people are at no increased risk of severe COVID-19H Chappell, R Patel, C Driessens, et al.
Gynecologic Oncology|March 26, 2005
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinomaF Y F L De Vos, A M E Bos, M Schaapveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOGC H Smorenburg, S M de Groot, A E van Leeuwen-Stok, et al.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2012
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel studyA K L Reyners, L de Munck, F L G Erdkamp, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|January 1, 1997
Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancerH de Graaf, W V Dolsma, P H Willemse, et al.
The Journal of Biological Chemistry|September 4, 2003
Alternative splicing of the actin binding domain of human cortactin affects cell migrationAgnes G S H van Rossum, Jos H de Graaf, Ellen Schuuring-Scholtes, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 19, 2014
Invasive Propionibacterium acnes infections in a non-selective patient cohort: clinical manifestations, management and outcomeM Tebruegge, C Jones, H de Graaf, et al.
Anticancer Research|November 1, 1995
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized diseaseH de Graaf, N H Mulder, P H Willemse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodesH de Graaf, P H Willemse, E G de Vries, et al.
The Journal of Infection|November 17, 2021
Immunocompromised children and young people are at no increased risk of severe COVID-19H Chappell, R Patel, C Driessens, et al.
Gynecologic Oncology|March 26, 2005
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinomaF Y F L De Vos, A M E Bos, M Schaapveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOGC H Smorenburg, S M de Groot, A E van Leeuwen-Stok, et al.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2012
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel studyA K L Reyners, L de Munck, F L G Erdkamp, et al.
Pageof 7